3 completed, 1 recruiting, 1 terminated, 1 unknown. 3 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow T Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of T Cell Non-Hodgkin Lymphoma trials Research Report on T Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) Senza5 CART5 - T Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Vittoria Biotherapeutics | 30 | 2024-10-04 | 2025-11-10 |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) RITA (App) - Multiple Myeloma, Solitary Plasmacytoma | Not applicable | Completed | Advice Pharma Group srl | 124 | 2022-06-04 | 2024-11-06 |
| Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies Fludarabine + Cyclophosphamide + CAR7-T Cells - T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia | Phase 1 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2021-04-15 | 2022-03-16 |
| Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma AUTO4 - T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Terminated | Autolus Limited | 20 | 2018-08-30 | 2026-03-16 |
| A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin - T Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 47 | 2013-07-16 | 2025-10-09 |
| Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma Imatinib mesylate - T Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 12 | 2008-06-01 | 2017-01-05 |
Lymphoma, T-Cell (6) · Amyloidosis (1) · Anemia, Refractory, with Excess of Blasts (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic, T-Cell (1) · Leukemia, T-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Multiple Myeloma (1) · Myeloproliferative Disorders (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma, Non-Hodgkin (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma (5) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Anemia (1) · Anemia, Refractory (1) · Behavior (1)
Carmustine (1) · Cyclophosphamide (1) · Cytarabine (1) · Drug Therapy (1) · Etoposide (1) · Imatinib Mesylate (1) · Melphalan (1) · fludarabine (1) · romidepsin (1)
Advice Pharma Group srl (1) · Autolus Limited (1) · Dana-Farber Cancer Institute (1) · Memorial Sloan Kettering Cancer Center (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Vittoria Biotherapeutics (1)
United States (3) · China (1) · Italy (1) · Spain (1) · United Kingdom (1)
Alessandro Flavio Ferri (1) · Eric Jacobsen, MD (1) · Heng Mei (1) · Steven Horowitz, MD (1)
PMID 25012943, PMID 39528665, PMID 40179392, PMID 41894682
2017 (1)